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1. Background
iabetic nephropathy (DN), is the lead-
ing cause of  kidney diseases in patients 
starting renal replacement therapy and 
affects approximately 40% of  type 1 and type 2 
diabetic(T2D) patients (1,2). It increases mortality 
mainly at the result of   cardiovascular complica-
tions, and is deﬁned by increased urinary albumin 
excretion in the absence of  other renal diseases 
(1). In spite of  widespread investigation on the 
etiology and  treatment of  DN, much less atten-
tion has been paid  to its association with lipopro-
D
ABSTRACT
Background: About 30-40% of  diabetic patients who developed nephropathy have li-
poprotein disorders, especially lipoprotein a [Lp(a)], which is related to atherosclerosis. 
Objectives: The aim of  this study was to investigate the effect of  N-acetyl cysteine 
(NAC) on the serum levels of  Lp(a) and amount of  proteinuria  in a group of  type 2 
diabetic patients with diabetic nephropathy. 
Patients and Methods: A total of  40, type 2 diabetic (T2D) patients, patients with protein-
uria, were randomly divided into two groups. The experimental group was treated by 
NAC (1200 mg/day) for two months in conjunction with conventional treatment for 
diabetes and hypertension. Control group received routine medications. 
Results: No signiﬁcant change was  identiﬁed in serum Lp(a)  during treatment with 
NAC (P >0.05). However, NAC decreased the amount of  proteinuria, serum triglyc-
eride (TG) level and systolic blood pressure in experimental group compared to the 
control group (P <0.05). 
Conclusions: These ﬁndings suggest that treatment with NAC has  no  signiﬁcant ef-
fect on the serum level of  Lp (a). However, it has beneﬁcial effects on the reduction 
of  proteinuria, serum TG level  and systolic blood pressure in T2D patients with ne-
phropathy. Further prospective studies are needed  to determine its full role. 
 Implication for health policy/practice/research/medical education:
This study was conducted to investigate the effect of  N-acetyl cysteine (NAC) on the serum level of  lipo-
protein (a) [Lp (a)] and the amount of  proteinuria in a group of  type 2 diabetic patients .In this investigation, 
there were no signiﬁcant changes in the serum Lp (a) during treatment with NAC. However, NAC decreased 
the amount of  proteinuria, serum triglyceride level and systolic blood pressure in type 2 diabetic patients. 
These ﬁndings suggest that NAC may be useful in the treatment of  proteinuria in these patients, although 
further prospective studies  are needed to determine  its full role.
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tein disorders, especially lipoprotein (a) [Lp(a)] 
which is a marker for atherosclerotic vascular dis-
ease progression (2-5). Elevated serum Lp(a) can 
be accompanied by renal dysfunction, higher risk 
of  atherosclerosis, and dyslipidemia. Moreover, 
an elevated Lp(a) serum level was associated with 
albuminuria in diabetic and non-diabetic patients 
(2). Therefore, reduction of  serum level of  Lp(a) 
can decrease the risk of  atherosclerotic vascular 
disease  and may improve nephropathy  in dia-
betic patients(6).
 Lipoproteins increase in individuals with a 
higher level of  Apo lipoproteins (7). It has been 
demonstrated that high levels of  Lp(a) are as-
sociated with brain infarction, coronary artery 
disease , and nephropathy (2-6). Lp(a) has an 
important role in the progression of  nephropa-
thy in patients with diabetes mellitus (DM) (6-
8). Furthermore, serum Lp(a) concentrations 
in patients with moderate diabetic nephropathy 
shows a considerable increase in the early stages 
of   renal disease (6).ﹶAlso the association of  Lp(a) 
with hypertension in diabetic patients has also 
been shown (9). N-acetyl-cysteine (NAC;C5H9–
NO3S) is generally being used as an antioxidant 
and insulin regulatory agent (10). Various stud-
ies have been conducted on the beneﬁcial effects 
of  antioxidant drugs, such as NAC, in reducing 
the risk of  atherosclerosis and its complications. 
In hemodialysis patients, treatment with NAC 
caused a reduction in serum Malondialdehyde 
(MDA) and cardiovascular events (11,12).  Most 
studies have shown that different drugs act on 
atherosclerosis by several mechanisms such as 
decreased apoptosis, vasoconstriction, and endo-
thelial dysfunction. NAC is an antioxidant agent 
and can break the disulﬁde bonds  so reduces the 
level of  Lp(a)(13,14) ,and with this in mind, this 
drug  was used as a treatment for  high levels of  
Lp(a) (13,14).However, the results were different 
and less data was published regarding the effect 
of  Lp(a) on progression of  nephropathy in T2D, 
and also modalities for high serum Lp(a).
 
2. Objectives
 The aim of  this study was to investigate the 
effects of  N-acetyl cysteine (NAC) on serum lev-
els of  Lp(a) in patients with T2D and proteinuria.
3. Patients and Methods
3.1. Patients
 Forty patients with T2D participated in this 
clinical trial. All patients gave informed consent, 
and all experiments and procedures were per-
formed in accordance with ethics committee of  
Shahrekord university of  medical sciences, Iran. 
Participants were divided into two aliquots groups 
I (interventional) and II (non-interventional).
 The inclusion criteria were the absence of  liv-
er and heart disease, patients who are not on lipid 
lowering medications, and absence of  unwanted 
or intolerable consequences of  NAC during drug 
use. Study subjects were randomly divided into 
two groups according to their age, body mass in-
dex (BMI), and duration of  DM. The ﬁrst group 
received NAC (600 mg every 12 hours orally) for 
2 months.  Patients in the second group received 
their routine medications. 
3.2. Laboratory tests
 Blood samples were collected for analysis af-
ter overnight fasting at the beginning and after 
2 months of  the study. Each specimen was col-
lected at room temperature and was allowed to 
clot over 15 minutes, centrifuged at 2000 g for 15 
minutes at 4°C, and separated sera were placed 
at -70°C until analysis . Total cholesterol (T-chol), 
plasma TG, high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol 
(LDL-C), fasting blood sugar (FBS), Alkaline 
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Phosphatase (ALP), BUN, creatinine (Cr), and 
liver enzymes(AST, ALT) were also measured by 
enzymatic method (Pars Azmun Kit, Iran) using 
auto-analyzer (BT 3000, France). For all patients, 
urine analysis was  also performed . HbA1c was 
determined by Biosystem kit (Spain) in accor-
dance with the instructions of  the manufacturer. 
An enzyme immunoassay (EIA) kit was used to 
measure Lp(a). In addition, blood pressure and 
blood proteins were measured for 24 hr. 
3.3. Statistical analysis 
 Data were expressed with mean ± SD. Statisti-
cal analysis of  the data was performed using the 
Statistics Package for Social Science (SPSS version 
13.0, SPSS Inc., Chicago, IL, USA). An indepen-
dent t-test was used to compare the mean of  the 
variables before and after  interventions. Differ-
ences were considered signiﬁcant at P < 0.05 level.
4. Results
 Table 1 shows that at the beginning of  the 
study, age, duration of  diabetes, and BMI were 
not signiﬁcantly different between two groups (p 
>0.05). Moreover, statistical analysis at the begin-
ning of  the study showed that both groups were 
biochemically and clinically similar (see Table 
2) and no signiﬁcant differences regarding bio-
chemical parameters were seen among  groups I 
and II (p>0.05).
Table 1. Comparison of  mean age, duration of  dia-
betes, and BMI in the study groups (groups I and II)
groups Mean ± SD P value
BMI
(kg/m2)
I* 27.56 ± 4.12 0.69
II** 28.09 ± 4.38
Age 
(year)
I 62.31 ± 9.32 0.30
II 59.15 ± 9.49
Duration of  
DM (year)
I 9.34 ±5.87 0.84
II 9 .00 ± 4.99
*I: Interventional, **II: Control group
 Table 3 demonstrates no signiﬁcant change 
in serum Lp(a), Cr, BUN, FBS, HbA1c, ALP, 
ALT,AST, LDL-C, HDL-C and  GFR between 
group I and II after treating with NAC (p > 
0.05). Signiﬁcant reduction of  proteinuria, sys-
tolic blood pressure, and TG level in group I 
compared to group II after the treatment with 
NAC  was observed (p < 0.001).
5. Discussion
 Previous studies have  demonstrated  Lp(a) 
as  an independent risk factor for coronary artery 
disease which  increases  considerably in patients 
with diabetic nephropathy (2-9). Furthermore, 
the level of  Lp (a) in patients with macroalbu-
minuria is higher than patients with microalbu-
minuria and  people with normal-albuminuria 
(15). It has been reported that Lp (a) increases 
in patients with diabetic nephropathy   , however 
in a  study  by  Kumari et al. , the results were 
different(16) . Correlation between serum Lp(a) 
and hypertension in T2D was reported by Nasri 
et al. ,while hypertension is an aggravating factor 
in DN(9). Moreover, a correlation between dia-
betic nephropathy and increased levels of  Lp(a) 
in diabetic patients was also observed (2,8,15-20). 
Previous studies proposed that NAC can reduce 
high levels of  Lp (a) due to its antioxidant prop-
erty (13,21-24). However, Wiklundo et al. found 
that  NAC  has  no signiﬁcant effect on the reduc-
tion of  serum Lp(a) (25). It seems that NAC has 
limited potency to reduce Lp(a) (25). In addition, 
the drug dosage and duration of  NAC treatment 
are also important factors which affect the efﬁ-
cacy of  this drug (6,25). To investigate the effect 
of  NAC on proteinuria and markers of  tubular 
injury in non-diabetic patients with chronic kid-
ney disease, a placebo-controlled, randomized, 
open, cross-over study, was conducted on 20 
non-diabetic patients with proteinuria with nor-
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mal or decreased kidney function. It was  found 
that NAC has  no effect on proteinuria, surrogate 
markers of  tubular injury or renal ﬁbrosis in non-
diabetic patients with chronic kidney disease (26). 
The possible effect of  NAC on the reduction of  
proteinuria may be due to its antioxidant prop-
erty (25-28). Also, the effect of  NAC on drug-
induced HTN as a result of  decreased blood 
pressure was investigated (28). In this regard, 
the positive effect of  NAC on the reduction of  
HTN , was shown (23). Likewise,  reduced  blood 
pressure in the NAC treated group was observed 
Table 2. Comparison of mean of variables in both groups before the intervention
P valueMean ± SDGroupsParametersP valueMean ± SDGroupsParameters
0.8619.50 ± 7.00ISGPT
(mg/dL)
0.9143.60 ± 12.40ILp(a) 
(mg/dL) 19.90 ± 6.50II42.70 ± 33.50II
0.5017.50 ± 3.00ISGOT 
(mg/dL)
0.91131.10 ± 19.10ISystolic BP
(mmHg) 18.30 ± 4.80II137.70 ± 11.00II
0.61212.70 ± 31.10IALP
(IU/mL)
0.2787.30 ± 7.50IDiastolic BP
(mmHg) 206.40 ± 44.9II90.00 ± 7.40II
0.1443.20 ± 8.80IHDL
(mg/dL)
0.308.60 ± 2.60IHbA1c
 % 39.20 ± 8.30II7.80 ± 2.00II
0.741.00 ± 0.50ICretinine
(mg/dL)
0.93186.70 ± 86.80IFBS 
(mg/dL) 1.00 ± 0.13II188.70 ± 46.40II
0.5238.00 ± 29.70IBun 
(mg/dL)
0.55214.10 ± 46.50ITC
(mg/dL) 33.50 ± 9.20II224.30 ± 59.00II
0.5786.30 ± 35.5IGFR (ml/
min/1.73 m2)
0.09175.70 ± 89.60ITG
(mg/dL) 81.20 ±18.00II232.00 ± 114.60II
0.2482.20 ±224.2IProteinuria 
(mg/day)
0.99117.80 ± 25.80ILDL
(mg/dL) 586.90 ± 188.7II117.90 ± 33.80II
Table 3. Comparison of the mean of variables in the two groups after intervention
Parameters Groups Mean ± SD P value Parameters Groups Mean ± SD P value
Lp(a)
(mg/dL)
I 33.60 ± 11.40 0.29 SGPT
(mg/dL)
I 20.00 ± 7.30 0.79
II 47.20 ± 53.90 II 19.50 ± 4.50
Systolic BP
(mmHg)
I 129.20 ± 5.80 0.04 SGOT
(mg/dL)
I 17.70 ± 3.50 0.66
II 134.00 ± 8.50 II 18.20 ± 3.10
Diastolic BP
(mmHg)
I 84.70 ± 4.50 0.09 ALP
(IU/mL)
I 201.20 ± 34.00 0.53
II 88.00 ± 7.10 II 193.80 ± 38.60
HbA1c
%
I 7.90 ± 1.90 0.89 HDL
(mg/dL)
I 41.92 ± 7.40 0.12
II 7.80 ± 1.40 II 38.40 ± 6.50
FBS
(mg/dL)
I 155.10 ± 68.00 0.51 Cretinine
(mg/dL)
I 1.00 ± 0.30 0.87
II 167.10 ± 45.10 II 1.00 ± 0.15
T-Chol
(mg/dL)
I 215.50 ± 48.10 0.79 Bun
(mg/dL)
I 36.80 ± 26.50 0.44
II 211.20 ± 56.00 II 32.00 ± 8.90
TG
(mg/dL)
I 169.70 ± 76.30 0.04 GFR
(ml/min)
I 83.90 ± 29.40 0.71
II 228.80 ± 99.80 II 80.80 ± 22.50
LDL
(mg/dL)
I 119.40 ± 25.90 0.88 Proteinuria
(mg/day)
I 381.70 ± 191.70 0.04
II 118.00 ± 32.10 II 499.00 ± 170.30
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in our study as well. The combinational effects 
of  L-argentine and NAC on the level of  blood 
pressure in  patients with diabetic nephropathy 
was studied by Martina et al. (29). They showed 
that L-arginine, is precursor for nitric oxide  bio-
synthesis. The combination of  L-argentine and 
NAC resulted in reduction of  both systolic and 
diastolic blood pressure. Furthermore, a signiﬁ-
cant decrease in other risk factors of  coronary 
artery disease such as total and LDL-C levels was 
observed (29). Also, our study showed the reduc-
tion of  SBP and serum TG levels compared to 
the control group. Similar result was observed on 
animal studies which showed the serum TG -low-
ering effect of  NAC  (30). In a clinical study on 
NAC, similar reduction of  TG and T-Chol, along 
with HDL-c elevation, was observed (31),how-
ever, no signiﬁcant change in  HDL-C was found 
in our study. 
6. Conclusions
 The results of  this study suggest  that treat-
ment with NAC  does  not  decrease  the serum 
level of  Lp (a) could reduce the amount of  pro-
teinuria, serum TG level, and SBP in patients 
with T2D and proteinuria. Further studies are 
needed to clarify the signiﬁcance of  our ﬁndings.
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